कंपनी का अवलोकन
Atara Biotherapeutics, Inc. is engaged in the development of transformative therapies designed to treat patients suffering from cancer and autoimmune diseases within the United States and internationally. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, where innovation in drug discovery and clinical trials is paramount for long-term value creation. Its operational scale is defined by a market capitalization of $39.50M, an annual revenue of $120.77M, and a workforce comprising 14 employees. These valuation and revenue figures indicate that the company holds a small-cap position in the biotechnology landscape, suggesting a high-risk, high-reward profile typical of firms still navigating the expensive process of advancing clinical programs like their lead product, Tab-cel.
वित्तीय स्वास्थ्य
The company reported a revenue of $120.77M for the trailing twelve months, accompanied by a net income of $32.69M and an EBITDA of $51.59M. The significant disparity between the revenue figure and the net income reveals a cost structure where non-operating expenses or one-time adjustments have impacted the bottom line despite positive operating earnings. However, the free cash flow stands at -$47,677,624, which indicates a substantial cash burn rate that constrains the company's immediate financial flexibility and necessitates reliance on external capital sources. The gross margin is reported at 61.8%, reflecting the high-margin nature of biotechnology product development, whereas the operating margin is -339.6%, signaling that operating expenses currently exceed operating revenue significantly. Despite the negative operating margin, the profit margin is stated as 27.1%, which presents an anomalous relationship between operating and net income that warrants careful scrutiny of non-operating income sources. The company holds $8.48M in cash against $10.38M in debt, resulting in a debt-to-equity ratio that is listed as N/A due to the negative equity position implied by the price-to-book ratio. The current ratio of 0.82 suggests that the company possesses less liquid assets than short-term liabilities, indicating potential pressure on short-term liquidity. Return on Equity is N/A, while the Return on Assets stands at 47.8%, revealing a high theoretical return on the asset base despite the lack of traditional equity value.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is 1.88, while the forward P/E is projected at 5.96, implying that the market expects earnings to increase significantly in the coming period to justify the higher forward multiple. The price-to-book ratio is -0.92, which indicates that the company's market valuation is below its book value, a common characteristic for biotechnology firms with negative equity or significant development costs capitalized off the books. Alternative valuation metrics such as the price-to-sales ratio of 0.33 and an EV/EBITDA of 0.80 suggest that the stock is priced at a deep discount relative to both its sales generation and its earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $19.14 and a 52-week low of $3.92, meaning the current price sits significantly below the 52-week high but well above the recent lows. The beta value is -0.33, indicating that the stock price moves inversely to the broader market or with a unique volatility profile that does not correlate positively with general market trends.
Growth & Income
Revenue growth year-over-year is recorded at -95.1%, while earnings growth is N/A, indicating that the company is currently shrinking in terms of top-line sales generation. Since earnings growth is not available, it is impossible to determine if earnings are growing faster or slower than revenue, but the negative revenue growth implies a contraction in the business segment or a shift in clinical trial spending recognition. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, effectively meaning that all available earnings are retained or used to fund operations and clinical development. The overall growth and income profile is characterized by significant revenue contraction and an absence of dividend income, typical of early-stage biotechnology companies focused on capital-intensive research rather than immediate profitability or shareholder distributions.